Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Inclusion Criteria:

• Histologic diagnosis of squamous cell carcinoma of esophagus. Preoperative stage Ⅱ-Ⅲ by endoscopic ultrasound, CT of the chest and abdomen,and esophagogram.
• Age ranges from 18 to 70 years.
• Patients must not have received any prior anticancer therapy.
• Performance status of 0 to 1
• Estimated life expectancy of at least 6 months.
• Tumor can be measured according to RECIST criteria
• Signed informed consent document on file.
• Females with childbearing potential must have a negative serum pregnancy
• Adequate organ function including the following:

Bone marrow: Absolute neutrophil count (ANC) greater than or equal 1.5×109/L Platelets greater than or equal 80×109/L Haemoglobin greater than or equal 80g/L Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN), Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN Renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment.

Exclusion Criteria:

• Carcinoma at the upper part of esophagus
• Histologic diagnosis of adenocarcinoma of esophagus.
• Prior treatment for esophageal cancer.
• Active infection.
• Pregnant or breast feeding.
• History of significant neurological or mental disorder, including seizures or dementia.
• Prior invasive malignancy in 5 years (except for carcinoma in situ).